Person:
TARIM, ÖMER FARUK

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

TARIM

First Name

ÖMER FARUK

Name

Search Results

Now showing 1 - 4 of 4
  • Publication
    Liver involvement in congenital hypopituitarism
    (Springer India, 2019-05-01) Altay, Derya; Eren, Erdal; EREN, ERDAL; Özkan, Tanju Başarır; Özgür, Taner; ÖZGÜR, TANER; Tarım, Ömer; TARIM, ÖMER FARUK; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-1684-1053; 0000-0001-5740-9729; 0000-0002-5322-5508; AAG-8381-2021; AAG-8416-2021; JPK-3909-2023
    ObjectiveCholestatic jaundice in early infancy is a complex diagnostic challenge. Cholestasis caused by endocrine disease is rare and poorly recognized. The aim of this paper is to report patients with liver dysfunctions resulting from hypopituitarism.MethodsSix patients with liver dysfunction diagnosed as hypopituitarism were studied and followed up atUludag University Faculty of Medicine.ResultsThe median age of the patients at first presentation was 2.5 mo. Three patients were diagnosed with congenital hypopituitarism at the first visit, and the other three were diagnosed during follow-up. Serum aminotransferase levels were very high in two patients and only moderately elevated in the others. Combined adrenal, thyroid, and growth hormone deficiencies were diagnosed in two patients, while remaining 4 patients had various combinations of adrenal, thyroid, and growth hormone deficiencies. Liver function abnormalities resolved between 10 d and 2 mo follow-up after hormone replacement therapy.ConclusionsAbnormal liver biochemical test results due to hormonal deficiencies in infants should be considered in the differential diagnosis by pediatricians. Hormone replacement therapy is the basis of treatment.
  • Publication
    Genotype and phenotype heterogeneity in neonatal diabetes: A single centre experience in Turkey
    (Galenos Yayıncılık, 2021-03-01) Öngen, Yasemin Denkboy; Eren, Erdal; Demirbaş, Özgecan; Sobu, Elif; Ellard, Sian; De Franco, Elisa; Tarım, Ömer; DENKBOY ÖNGEN, YASEMİN; EREN, ERDAL; DEMİRBAŞ, ÖZGECAN; Sobu, Elif; TARIM, ÖMER FARUK; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Endokrinolojisi Anabilim Dalı.; 0000-0002-5657-4260; 0000-0002-1684-1053; 0000-0002-6922-5203; 0000-0002-2037-7046; 0000-0002-5322-5508; KHZ-1491-2024 ; JPK-3909-2023; GQX-9760-2022 ; GSN-9730-2022; CCU-8073-2022
    Objective: Neonatal diabetes mellitus (NDM) may be transient or permanent, and the majority is caused by genetic mutations. Early diagnosis is essential to select the patients who will respond to oral treatment. In this investigation, we aimed to present the phenotype and genotype of our patients with NDM and share our experience in a single tertiary center.Methods: A total of 16 NDM patients from 12 unrelated families are included in the study. The clinical presentation, age at diagnosis, perinatal and family history, consanguinity, gender, hemoglobin A1c, C-peptide, insulin, insulin autoantibodies, genetic mutations, and response to treatment are retrospectively evaluated.Results: The median age at diagnosis of diabetes was five months (4 days-18 months) although six patients with a confirmed genetic diagnosis were diagnosed >6 months. Three patients had KCNJ11 mutations, six had ABCC8 mutations, three had EIF2AK3 mutations, and one had a de novo INS mutation. All the permanent NDM patients with KCNJ11 and ABCC8 mutations were started on sulfonylurea treatment resulting in a significant increase in C-peptide level, better glycemic control, and discontinuation of insulin.Conclusion: Although NDM is defined as diabetes diagnosed during the first six months of life, and a diagnosis of type 1 diabetes is more common between the ages of 6 and 24 months, in rare cases NDM may present as late as 12 or even 24 months of age. Molecular diagnosis in NDM is important for planning treatment and predicting prognosis. Therefore, genetic testing is essential in these patients.
  • Publication
    Clinical and laboratory follow up of pediatric craniopharyngioma cases
    (Bursa Uludag Universitesi, 2020-12-01) Sobu, Elif; Eren, Erdal; Sevinir, Betul; Taşkapılıoğlu, M. Özgür; Tarim, Omer; EREN, ERDAL; Sevinir, Betul; SEVİNİR, BETÜL BERRİN; Tarım, Ömer; TARIM, ÖMER FARUK; Bursa Uludağ Üniveristesi/Tıp Fakültesi; 0000-0002-1684-1053; 0000-0002-3232-7652; 0000-0001-5472-9065; 0000-0002-5322-5508; GSN-9730-2022; JPK-3909-2023; AAH-1570-2021
    INTRODUCTION: The aim of this study was to evaluate the clinical and laboratory findings and follow up of endocrine status of pediatric craniopharyngioma cases.MATERIALS and METHODS: The patients diagnosed with craniopharyngioma between January 2010-December 2017 were included in this study. Demographic and clinical findings were retrospectively examined from medical records of Uludag University Medical Faculty Pediatric Endocinology Department. Statistical analyses were performed using the SPSS software version 21.RESULTS: We identified a total of 28 patients with craniopharyngioma during this period. The age of the patients ranged from 60 to 207 months, with a median age of 138.5 months. Fifty-three percent (n=15) of cases were male and forty-seven percent (n=13) of the cases were female. The most common presenting complaints were headache, visual impairment, and short stature in decreasing order. Tumor size was greater than 3 cm in 71% (n: 20) of patients at the time of diagnosis. When the endocrine status of the patients were examined in the preoperative period, it was determined that 17% (n: 5) of the cases had growth hormone deficiency, 14% (n: 4) had hypothyroidism, 10% (n: 3) had cortisol deficiency, and 7.1% (n: 2) had diabetes insipidus. In the postoperative period, panhypopituitarism developed in 89.3% (n: 25) of the cases.CONCLUSIONS: Craniopharyngiomas are slow-growing tumors, the tumor is usually diagnosed late and reaches large sizes. Late diagnosis and large tumor size often lead to more serious endocrine losses. Failure to thrive and progressive weight gain are stimulating findings for early diagnosis of pituitary masses.
  • Publication
    Telemedicine experiences at a pediatric endocrinology clinic during the COVID-19 pandemic
    (Springer, 2021-06-07) Denkboy Öngen, Yasemin; Eren, Erdal; Şahin, Kadriye Cansu; Buhur Pirimoğlu, Meltem; Sağlam, Halil; Tarim, Ömer; DENKBOY ÖNGEN, YASEMİN; EREN, ERDAL; ŞAHİN, KADRİYE CANSU; BUHUR PİRİMOĞLU, MELTEM; SAĞLAM, HALİL; TARIM, ÖMER FARUK; Bursa Uludağ Üniversitesi/Çocuk Endokrinolojisi Anabilim Dalı; 0000-0002-1684-1053; 0000-0002-6598-8262; 0000-0002-5657-4260; KHZ-1491-2024; JPK-3909-2023; GLN-8241-2022; CCU-8073-2022
    Background The coronavirus 19 (COVID-19) pandemic has affected all aspects of life, including the routine follow-up of patients with chronic illnesses. In this study, we aim to share our experience of telemedicine in our pediatric endocrinology clinic during the pandemic. Methods We were able to continue caring for children with endocrine disorders using various communication methods such as e-mail and e-message. Results A total of 267 patients received telemedicine care over the course of 608 contacts. The number of hospital visits and physical contact was effectively reduced to help protect against the COVID-19 infection. The patients were supported in terms of receiving their prescriptions and patient education also continued. No complications were observed. Conclusion The advantages and disadvantages of telemedicine were discussed and consequently, we propose that telemedicine can be utilized to maintain and continue the care of children with endocrine disorders during and even after the pandemic. Further studies are needed to standardize this method for general use.